Literature DB >> 20552497

Anatomical and functional differences between the Paced Auditory Serial Addition Test and the Symbol Digit Modalities Test.

Cristina Forn1, Antonio Belenguer, Vicente Belloch, Ana Sanjuan, M Antonia Parcet, Cesar Avila.   

Abstract

The Paced Auditory Serial Addition Test (PASAT) and the Symbol Digit Modalities Test (SDMT) are generally used to detect cognitive impairments in multiple sclerosis patients. Although both seem to be sensitive to the slow information-processing speed, some results suggest that they do not involve the same cognitive functions. The aim of the present study is to observe possible differences between these tasks to help understand their utility to cognitive assessment. A total of 17 participants were recruited for the study and completed a block-design version of each task. Comparisons between tasks were calculated using an analysis of variance (ANOVA; p < .05, familywise error, FWE, corrected). We observed activations in the left frontal and parietal areas during both tasks; however, the PASAT activated more frontal areas than did the SDMT. These tasks require an efficient transfer of information among large areas. Moreover, the PASAT requires more executive functions to be executed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20552497     DOI: 10.1080/13803395.2010.481620

Source DB:  PubMed          Journal:  J Clin Exp Neuropsychol        ISSN: 1380-3395            Impact factor:   2.475


  14 in total

1.  Analysis of "task-positive" and "task-negative" functional networks during the performance of the Symbol Digit Modalities Test in patients at presentation with clinically isolated syndrome suggestive of multiple sclerosis.

Authors:  C Forn; M A Rocca; I Boscá; B Casanova; A Sanjuan; M Filippi
Journal:  Exp Brain Res       Date:  2013-01-04       Impact factor: 1.972

2.  Neurofunctional correlates of attention rehabilitation in Parkinson's disease: an explorative study.

Authors:  Antonio Cerasa; Maria Cecilia Gioia; Maria Salsone; Giulia Donzuso; Carmelina Chiriaco; Sabrina Realmuto; Alessandra Nicoletti; Gabriele Bellavia; Aurelia Banco; Marco D'amelio; Mario Zappia; Aldo Quattrone
Journal:  Neurol Sci       Date:  2014-02-20       Impact factor: 3.307

3.  Hippocampal volume is related to cognitive decline and fornicial diffusion measures in multiple sclerosis.

Authors:  Katherine A Koenig; Ken E Sakaie; Mark J Lowe; Jian Lin; Lael Stone; Robert A Bermel; Erik B Beall; Stephen M Rao; Bruce D Trapp; Micheal D Phillips
Journal:  Magn Reson Imaging       Date:  2013-12-30       Impact factor: 2.546

4.  Neuroinflammatory component of gray matter pathology in multiple sclerosis.

Authors:  Elena Herranz; Costanza Giannì; Céline Louapre; Constantina A Treaba; Sindhuja T Govindarajan; Russell Ouellette; Marco L Loggia; Jacob A Sloane; Nancy Madigan; David Izquierdo-Garcia; Noreen Ward; Gabriel Mangeat; Tobias Granberg; Eric C Klawiter; Ciprian Catana; Jacob M Hooker; Norman Taylor; Carolina Ionete; Revere P Kinkel; Caterina Mainero
Journal:  Ann Neurol       Date:  2016-10-25       Impact factor: 10.422

5.  Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive battery.

Authors:  Chris Edgar; Peter J Jongen; Evert Sanders; Christian Sindic; Sophie Goffette; Michel Dupuis; Philippe Jacquerye; Daniel Guillaume; Regine Reznik; Keith Wesnes
Journal:  BMC Neurol       Date:  2011-06-07       Impact factor: 2.474

6.  Relations between Concurrent Longitudinal Changes in Cognition, Depressive Symptoms, Self-Rated Health and Everyday Function in Normally Aging Octogenarians.

Authors:  Elisabet Classon; Katarina Fällman; Ewa Wressle; Jan Marcusson
Journal:  PLoS One       Date:  2016-08-23       Impact factor: 3.240

7.  The association between intra- and juxta-cortical pathology and cognitive impairment in multiple sclerosis by quantitative T2* mapping at 7 T MRI.

Authors:  Céline Louapre; Sindhuja T Govindarajan; Costanza Giannì; Nancy Madigan; A Scott Nielsen; Jacob A Sloane; Revere P Kinkel; Caterina Mainero
Journal:  Neuroimage Clin       Date:  2016-11-03       Impact factor: 4.881

8.  Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).

Authors:  Giancarlo Comi; Francesco Patti; Maria Assunta Rocca; Flavia Caterina Mattioli; Maria Pia Amato; Paolo Gallo; Diego Centonze; Carlo Pozzilli; Francesco Saccà; Florian Then Bergh; Marta Bartezaghi; Renato Turrini; Massimo Filippi
Journal:  J Neurol       Date:  2017-10-23       Impact factor: 4.849

9.  Cerebellar abnormalities contribute to disability including cognitive impairment in multiple sclerosis.

Authors:  Katrin Weier; Iris K Penner; Stefano Magon; Michael Amann; Yvonne Naegelin; Michaela Andelova; Tobias Derfuss; Christoph Stippich; Ernst-Wilhelm Radue; Ludwig Kappos; Till Sprenger
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

10.  Microstructural network alterations of olfactory dysfunction in newly diagnosed Parkinson's disease.

Authors:  Ming-Ching Wen; Zheyu Xu; Zhonghao Lu; Ling Ling Chan; Eng King Tan; Louis C S Tan
Journal:  Sci Rep       Date:  2017-10-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.